Fmr LLC Buys 251,085 Shares of Genomic Health, Inc. (GHDX)

Fmr LLC grew its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 83.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 550,627 shares of the medical research company’s stock after buying an additional 251,085 shares during the period. Fmr LLC’s holdings in Genomic Health were worth $35,466,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Royce & Associates LP increased its position in Genomic Health by 22.8% during the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after buying an additional 273 shares in the last quarter. Advisor Group Inc. increased its position in Genomic Health by 34.9% during the fourth quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after buying an additional 516 shares in the last quarter. Pacer Advisors Inc. purchased a new position in Genomic Health during the third quarter worth $171,000. Quantamental Technologies LLC purchased a new position in Genomic Health during the fourth quarter worth $180,000. Finally, Amalgamated Bank purchased a new position in Genomic Health during the fourth quarter worth $203,000. 90.60% of the stock is owned by institutional investors.

In other news, CFO G Bradley Cole sold 15,000 shares of Genomic Health stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $67.61, for a total value of $1,014,150.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker sold 600 shares of Genomic Health stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $76.20, for a total value of $45,720.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,246,252 shares of company stock valued at $163,036,665. Company insiders own 45.80% of the company’s stock.

Several equities analysts have weighed in on GHDX shares. BidaskClub raised Genomic Health from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 9th. Needham & Company LLC started coverage on Genomic Health in a research report on Wednesday, January 2nd. They set a “strong-buy” rating and a $86.00 price target for the company. Piper Jaffray Companies raised their price target on Genomic Health to $86.00 and gave the stock a “neutral” rating in a research report on Thursday, February 21st. Finally, ValuEngine downgraded Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 5th. Ten equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $63.13.

Shares of NASDAQ:GHDX opened at $61.93 on Friday. The firm has a market capitalization of $2.29 billion, a PE ratio of 58.42 and a beta of 0.95. Genomic Health, Inc. has a 52 week low of $31.05 and a 52 week high of $92.18.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.02. The business had revenue of $104.56 million during the quarter, compared to the consensus estimate of $101.55 million. Genomic Health had a return on equity of 16.86% and a net margin of 6.52%. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.05 earnings per share. As a group, analysts expect that Genomic Health, Inc. will post 1.49 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/fmr-llc-buys-251085-shares-of-genomic-health-inc-ghdx.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: What is range trading?

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.